Viemed Healthcare board authorizes share repurchase program up to 5%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2025
0mins
Share Repurchase Program: Viemed Healthcare's Board of Directors has approved a share repurchase program allowing the company to buy back up to 1,976,441 common shares until June 2026, representing about 5% of its total shares as of March 31, 2025.
Purchase Guidelines: The repurchases will be conducted in compliance with securities laws, primarily through open market or block purchases, with daily buying limited to 25% of the average daily volume from the previous four weeks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VMD
About VMD
Viemed Healthcare, Inc. is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. The Company focuses on in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment solutions, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, oxygen concentrators, breast pumps for women, respiratory devices and other medical equipment. It offers in-home sleep apnea testing services. The Company also provides healthcare staffing and recruitment services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viemed Healthcare Exceeds Q1 2026 Earnings Expectations
- Significant Revenue Growth: Viemed Healthcare reported Q1 revenue of $75.4 million, a 28% increase year-over-year, demonstrating the company's ongoing expansion in sleep and maternal health sectors, thereby enhancing its market competitiveness.
- Improved Cash Flow: The company generated free cash flow of $2.6 million, a notable recovery from a negative $5.7 million in Q1 2025, indicating progress in capital efficiency and strengthening financial stability.
- Guidance Upgrade: Viemed raised its 2026 net revenue guidance to a range of $312 million to $320 million, reflecting confidence in future performance, while also adjusting capital expenditure expectations to 9% to 10.5% of net revenue, highlighting a focus on capital utilization efficiency.
- Patient Churn Risk: Despite strong momentum in new patient starts, the turnover rate is higher than expected due to NCD compliance issues, resulting in a net patient census of 12,089 at quarter-end, which poses short-term pressure on performance.
See More
Viemed Healthcare Q1 Earnings Beat Expectations with Strong Revenue Growth
- Significant Revenue Growth: Viemed Healthcare reported Q1 revenue of $75.41 million, reflecting a 27.5% year-over-year increase, exceeding market expectations by $1.01 million, indicating strong demand and an increase in market share in the medical equipment sector.
- Adjusted EBITDA Increase: The adjusted EBITDA for the quarter ended March 31, 2026, totaled $14.3 million, representing a 12% increase compared to the same period last year, showcasing ongoing improvements in operational efficiency and cost control, which enhance profitability.
- Strong Cash Flow Performance: The net cash provided by operating activities for the quarter was $8.1 million, with a total of $57.1 million over the trailing twelve months, demonstrating robust cash management that supports future investments and expansion.
- Updated 2026 Guidance: The company has revised its 2026 revenue guidance to a range of $312 million to $320 million, up from the previous range, reflecting positive trends in new patient starts and an optimized revenue mix, which further boosts market confidence.
See More
Viemed Healthcare to Announce Q1 Earnings on May 6
- Earnings Announcement: Viemed Healthcare is set to release its Q1 earnings on May 6 before market open, with a consensus EPS estimate of $0.09, reflecting a significant 50% year-over-year increase, indicating strong profitability improvements.
- Revenue Expectations: Analysts forecast that VMD's Q1 revenue will reach $74.4 million, representing a 25.9% year-over-year growth, which will further solidify the company's market position in the healthcare sector.
- Performance Beat Record: Over the past year, Viemed Healthcare has beaten EPS and revenue estimates 75% of the time, demonstrating the company's financial stability and effective management execution.
- Share Repurchase Program: Viemed Healthcare has authorized a share repurchase program through March 2027, which not only reflects the company's confidence in its stock value but also has the potential to provide additional returns to shareholders.
See More
Viemed to Host Q1 2026 Earnings Call on May 6
- Earnings Call Announcement: Viemed Healthcare will host its Q1 2026 earnings conference call on May 6, 2026, at 11:00 a.m. EDT, aimed at providing investors and analysts with updates on financial performance and business developments.
- Participation Details: Interested parties can join the call by dialing 877-407-6176 (US Toll-Free) or +1 201-689-8451 (International), ensuring global investors have convenient access to company information.
- Live Audio Webcast: The call will be available via a live audio webcast, accessible through the provided link, which enhances transparency and broadens the reach of information dissemination, thereby strengthening investor relations.
- Replay Availability: Following the live call, a replay will be accessible in the Investor Relations section of the company's website, ensuring that investors who cannot participate in real-time can still obtain relevant information, thus improving communication efficiency between the company and its investors.
See More
Viemed (VMD) Q4 2025 Earnings Call Transcript
See More
Viemed Healthcare Q4 Earnings Beat Expectations
- Earnings Highlights: Viemed Healthcare reported Q4 GAAP EPS of $0.14, beating expectations by $0.05, although revenue of $76.2 million, up 25.5% year-over-year, missed by $1.15 million, indicating challenges in balancing growth and profitability.
- Adjusted EBITDA Growth: For the year ending December 31, 2025, adjusted EBITDA reached $18.2 million, with a record $61.4 million for the full year, demonstrating the company's ability to maintain strong profitability amid ongoing growth, which bolsters investor confidence.
- Significant Free Cash Flow Increase: The free cash flow for 2025 totaled $28.1 million, a substantial increase from $11.6 million in 2024, reflecting improvements in operational efficiency and cash management, which will support future investments and shareholder returns.
- 2026 Financial Guidance: The company expects net revenue for 2026 to be in the range of $310 million to $320 million, below the market consensus of $328.73 million, with adjusted EBITDA projected between $65 million and $69 million, indicating a cautiously optimistic outlook for future growth.
See More
Viemed Healthcare Exceeds Q1 2026 Earnings Expectations
- Significant Revenue Growth: Viemed Healthcare reported Q1 revenue of $75.4 million, a 28% increase year-over-year, demonstrating the company's ongoing expansion in sleep and maternal health sectors, thereby enhancing its market competitiveness.
- Improved Cash Flow: The company generated free cash flow of $2.6 million, a notable recovery from a negative $5.7 million in Q1 2025, indicating progress in capital efficiency and strengthening financial stability.
- Guidance Upgrade: Viemed raised its 2026 net revenue guidance to a range of $312 million to $320 million, reflecting confidence in future performance, while also adjusting capital expenditure expectations to 9% to 10.5% of net revenue, highlighting a focus on capital utilization efficiency.
- Patient Churn Risk: Despite strong momentum in new patient starts, the turnover rate is higher than expected due to NCD compliance issues, resulting in a net patient census of 12,089 at quarter-end, which poses short-term pressure on performance.
See More
Viemed Healthcare Q1 Earnings Beat Expectations with Strong Revenue Growth
- Significant Revenue Growth: Viemed Healthcare reported Q1 revenue of $75.41 million, reflecting a 27.5% year-over-year increase, exceeding market expectations by $1.01 million, indicating strong demand and an increase in market share in the medical equipment sector.
- Adjusted EBITDA Increase: The adjusted EBITDA for the quarter ended March 31, 2026, totaled $14.3 million, representing a 12% increase compared to the same period last year, showcasing ongoing improvements in operational efficiency and cost control, which enhance profitability.
- Strong Cash Flow Performance: The net cash provided by operating activities for the quarter was $8.1 million, with a total of $57.1 million over the trailing twelve months, demonstrating robust cash management that supports future investments and expansion.
- Updated 2026 Guidance: The company has revised its 2026 revenue guidance to a range of $312 million to $320 million, up from the previous range, reflecting positive trends in new patient starts and an optimized revenue mix, which further boosts market confidence.
See More
Viemed Healthcare to Announce Q1 Earnings on May 6
- Earnings Announcement: Viemed Healthcare is set to release its Q1 earnings on May 6 before market open, with a consensus EPS estimate of $0.09, reflecting a significant 50% year-over-year increase, indicating strong profitability improvements.
- Revenue Expectations: Analysts forecast that VMD's Q1 revenue will reach $74.4 million, representing a 25.9% year-over-year growth, which will further solidify the company's market position in the healthcare sector.
- Performance Beat Record: Over the past year, Viemed Healthcare has beaten EPS and revenue estimates 75% of the time, demonstrating the company's financial stability and effective management execution.
- Share Repurchase Program: Viemed Healthcare has authorized a share repurchase program through March 2027, which not only reflects the company's confidence in its stock value but also has the potential to provide additional returns to shareholders.
See More
Viemed to Host Q1 2026 Earnings Call on May 6
- Earnings Call Announcement: Viemed Healthcare will host its Q1 2026 earnings conference call on May 6, 2026, at 11:00 a.m. EDT, aimed at providing investors and analysts with updates on financial performance and business developments.
- Participation Details: Interested parties can join the call by dialing 877-407-6176 (US Toll-Free) or +1 201-689-8451 (International), ensuring global investors have convenient access to company information.
- Live Audio Webcast: The call will be available via a live audio webcast, accessible through the provided link, which enhances transparency and broadens the reach of information dissemination, thereby strengthening investor relations.
- Replay Availability: Following the live call, a replay will be accessible in the Investor Relations section of the company's website, ensuring that investors who cannot participate in real-time can still obtain relevant information, thus improving communication efficiency between the company and its investors.
See More
Viemed (VMD) Q4 2025 Earnings Call Transcript
See More
Viemed Healthcare Q4 Earnings Beat Expectations
- Earnings Highlights: Viemed Healthcare reported Q4 GAAP EPS of $0.14, beating expectations by $0.05, although revenue of $76.2 million, up 25.5% year-over-year, missed by $1.15 million, indicating challenges in balancing growth and profitability.
- Adjusted EBITDA Growth: For the year ending December 31, 2025, adjusted EBITDA reached $18.2 million, with a record $61.4 million for the full year, demonstrating the company's ability to maintain strong profitability amid ongoing growth, which bolsters investor confidence.
- Significant Free Cash Flow Increase: The free cash flow for 2025 totaled $28.1 million, a substantial increase from $11.6 million in 2024, reflecting improvements in operational efficiency and cash management, which will support future investments and shareholder returns.
- 2026 Financial Guidance: The company expects net revenue for 2026 to be in the range of $310 million to $320 million, below the market consensus of $328.73 million, with adjusted EBITDA projected between $65 million and $69 million, indicating a cautiously optimistic outlook for future growth.
See More
